Figure 4
Figure 4. Liposome-clodronate macrophage depletion relieves VWD type 2B–associated thrombocytopenia. (A) VWF:Ag levels were measured in mice before and 24 hours after treatment with liposome-PBS or liposome-clodronate. VWF:Ag levels after treatment were compared with those before treatment. Antigen levels before treatment were arbitrarily set at 100%. (B-D) Platelet counts were determined in mice expressing wt-mVWF (B), p.V1316M-mVWF (C), or p.R1306Q-mVWF (D) before and 24 and 48 hours after injection with liposome-PBS or liposome-clodronate. Data represent mean ± SEM of 3 injected mice/treatment.

Liposome-clodronate macrophage depletion relieves VWD type 2B–associated thrombocytopenia. (A) VWF:Ag levels were measured in mice before and 24 hours after treatment with liposome-PBS or liposome-clodronate. VWF:Ag levels after treatment were compared with those before treatment. Antigen levels before treatment were arbitrarily set at 100%. (B-D) Platelet counts were determined in mice expressing wt-mVWF (B), p.V1316M-mVWF (C), or p.R1306Q-mVWF (D) before and 24 and 48 hours after injection with liposome-PBS or liposome-clodronate. Data represent mean ± SEM of 3 injected mice/treatment.

Close Modal

or Create an Account

Close Modal
Close Modal